Franklin, Tennessee (PRWEB) December 02, 2014
DiaTech Oncology, provider of CorrectChemo, the industry leading functional drug response profiling test to help oncologists provide personalized cancer treatment, has received regulatory approval from CLIA (Clinical laboratory Improvement Amendments 1988) to perform the test in its Franklin, Tennessee-based lab. The lab will provide testing services for US patients along with the company’s current lab in Montreal.
“We test a wide variety of approved chemo agents on live cancer cells with a commitment to deliver results in three days or less to patients and providers,” says Robert E. Henry, president and chief executive officer. “Having our CLIA approved lab adjacent to our headquarters in Middle Tennessee makes that commitment even easier to achieve.”
The CorrectChemo Assay, developed by DiaTech, is the only diagnostic test available that identifies, within 72 hours, how effective a variety of chemotherapy drugs may be in killing cancer cells in an individual patient sample. This patient-specific cancer testing allows oncologists to develop a treatment plan tailored to each patient’s individual chemotherapy needs. The test has already posted groundbreaking results in expanding survival rates – a 28 percent increase for breast cancer patients; and a 68 percent increase for ovarian cancer patients. With more than 1,500 tests completed to date, DiaTech expects volume to increase with an expansion of capacity.
The Franklin lab also enables the company to continue research and development efforts. DiaTech’s Montreal lab has been online since 2004. All clinical trials for the assay were conducted there, in partnership with McGill University.
About DiaTech Oncology
Founded in 2003 DiaTech Oncology (DiaTech) is a privately held international life sciences company based in Nashville Tennessee with laboratories in the United States and Canada. As a certified clinical pathology laboratory DiaTech is focused exclusively on the analysis of live cancer cells and their reaction to individual chemotherapy agents to determine the most effective apoptosis (cell death) rate. DiaTech has the exclusive and perpetual licensing rights for technology developed by researchers at Vanderbilt University as the MiCK® Assay.